Introduction {#sec1}
============

The 2019 novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a coronavirus disease 2019 (COVID-19) pandemic, with 3 million people contracting the disease and 208,131 cases resulting in death globally at the time of this writing (April 27, 2020).[@bib1] COVID-19 is usually mild in 81%, severe in 14%, and critical in 5% of nonpregnant patients,[@bib2] percentages which are similar (86%, 9%, and 5%, respectively) to pregnant women in early reports.[@bib3] AJOG MFM at a GlanceWhy was this study conducted?This study aimed to describe the clinical course of severe or critical coronavirus disease 2019 (COVID-19) in hospitalized pregnant patients so that healthcare providers have guidance regarding antepartum and delivery management.Key findingsPregnant women with severe or critical COVID-19 were admitted to the hospital about 7 days after the onset of symptoms and stayed in the hospital for 6 days (median, 6 days \[severe group\] and 10.5 days \[critical group\]; *P*=.01). Intubation was usually performed around day 9 on patients who required it; peak respiratory support for women with severe conditions was performed on day 8. Hospitalization of pregnant women with severe or critical COVID-19 resulted in delivery during the course of the disease in 50% of this cohort. Furthermore, 75% of all women with critical COVID-19 had mostly iatrogenic preterm delivery.What does this add to what is known?These data add significantly to the body of literature regarding the clinical course of severe or critical COVID-19 in pregnancy and suggest that the clinical course of severe or critical COVID-19 in hospitalized pregnant women may be shorter than in hospitalized nonpregnant patients.

The clinical course of severe or critical COVID-19 in nonpregnant patients includes hospital admission occurring at a median of 7 days after the onset of symptoms, dyspnea on day 8, sepsis on day 9, acute respiratory distress syndrome (ARDS) on days 9--12, intensive care unit (ICU) admission and mechanical ventilation on days 10.5--12, and death or discharge for survivors on day 21; the median length of hospital stay in nonpregnant patients is about 12 days.[@bib4], [@bib5], [@bib6]; however, there is very limited information regarding the clinical course of severe and critical COVID-19 in hospitalized pregnant women. In a cohort of 15 pregnant women in China, the interval from symptom onset to admission varied from 2 to 10 days, and no other clinical course details were provided.[@bib7]

Knowledge of the clinical course of the disease is vital to answering questions about the management of pregnant women with COVID-19. The physiological changes in pregnancy affect lung volumes and immune response and therefore have the potential to affect the clinical course of COVID-19 in pregnancy. To be able to answer questions about optimal management, timing of delivery, and various medications used for obstetrical indications, the clinical course of the maternal disease must be understood. The physiological changes in pregnancy, particularly those related to disease severity, progression, and outcomes, also need to be more clearly elucidated.

This study aimed to describe the clinical course of severe and critical COVID-19 in pregnant women during hospitalization.

Materials and Methods {#sec2}
=====================

Study design {#sec2.1}
------------

A multicenter cohort study was performed on pregnant women admitted to the hospital for treatment of severe or critical COVID-19 from March 5, 2020 to April 20, 2020, to determine the clinical course of the disease. To maximize the number of cases, this study was of both retrospective and prospective nature. It was designed in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cohort studies before data collection.[@bib8] Institutional review board (IRB) approval was obtained from the primary site, Thomas Jefferson University (IRB control number 20E.397). Collaborating sites obtained IRB approval or data use agreements with Thomas Jefferson University, when required by their institution.

Inclusion criteria were all pregnant and current postpartum women with positive laboratory testing for SARS-CoV-2, criteria that meet the diagnosis of severe or critical COVID-19 as defined by the Chinese Center for Disease Control and Prevention.[@bib9] Severe COVID-19 was defined as dyspnea, respiratory rate ≥30 breaths per minute, blood oxygen saturation ≤93% on room air, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen \<300 mm Hg, or lung infiltrates \>50% within 24--48 hours of symptom onset.[@bib9] For the purpose of the definition of severe disease in this study, "dyspnea" was defined as patient-reported dyspnea at rest. Critical COVID-19 was defined as respiratory failure requiring mechanical ventilation, septic shock, or multiple organ dysfunction or failure.[@bib9] Respiratory failure was defined as a need for invasive mechanical ventilation. Septic shock was defined as ≥2 Sequential (sepsis-related) Organ Failure Assessment (SOFA) criteria (decline in ratio of partial pressure of oxygen to fraction of inspired oxygen, decline in platelets, rising bilirubin, decline in mean arterial pressure \[MAP\], decline in Glasgow Coma Scale, and rise in serum creatinine) and need for vasopressors to maintain a MAP of ≥65 mm Hg and serum lactate of \>2 mmol/L even with sufficient volume resuscitation.[@bib10] Women were considered to have multiple organ dysfunction or failure if they had evidence of at least 2 of the following: renal impairment or failure (defined as a 3-fold increase in baseline creatinine or need for dialysis[@bib11]), liver failure (international normalized ratio \[INR\]\>1.5), refractory hypoglycemia as diagnosed by the treating institution, or hepatic encephalopathy.[@bib12] Women with inconclusive or negative testing for SARS-CoV-2 (even if clinical suspicion was high) and women who received a diagnosis of COVID-19 \>7 days after delivery were excluded.

The primary outcome was median duration (from hospital admission to discharge) overall and for women with severe vs critical COVID-19. This outcome was chosen as a surrogate for the duration of illness requiring support. Secondary maternal outcomes focused on the clinical course of COVID-19, with the day of symptom onset being defined as disease day 1. The variables of the clinical course examined included disease day of oxygen supplementation, other respiratory support, intubation and extubation, day of peak respiratory support, and day of return to room air. Data were also recorded on new-onset cardiomyopathy, cardiac arrest, and death. Disease day of delivery, if applicable, was included. Peak levels of various serum laboratory markers as well as the peak day of laboratory value if it was drawn ≥3 times were recorded. Additional data were collected on the duration of hospitalization, treatment modalities, obstetrical outcomes, and neonatal outcomes.

Data collection {#sec2.2}
---------------

Investigators at each institution reviewed the electronic medical record of women and any delivered neonate, and deidentified data were recorded and stored in a standardized computer spreadsheet. Data were reviewed by coinvestigators and compiled for analysis.

Statistical analysis {#sec2.3}
--------------------

Statistical analysis included means and standard deviations for normally distributed data, medians with interquartile ranges (IQRs), and percentages. The groups were compared using the *t*-test, analysis of variance, Mann-Whitney *U* test, χ^2^ test, and Fisher exact test. Analysis was performed for severe and critical disease separately, as well as for the entire cohort.

Results {#sec3}
=======

Twelve institutions provided data: Pennsylvania (n=6), New York (n=3), New Jersey (n=2), and Ohio (n=1). Of 64 women included, 44 (69%) had severe disease, and 20 (31%) met the criteria for critical COVID-19 ([Figure 1](#fig1){ref-type="fig"} ).Figure 1Flow diagram of included womenFlowchart of women with severe or critical COVID-19 during pregnancy.*COVID-19*, coronavirus disease 2019.*Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. AJOG MFM 2020.*

Maternal demographics are shown in [Table 1](#tbl1){ref-type="table"} . Overall, the mean age was 33 years; women with critical disease were significantly older than women with severe disease. Average body mass index was 34 kg/m^2^. Among 64 women, 21 (31%) were Hispanic, 18 (28%) were non-Hispanic black, and 16 (25%) were non-Hispanic white. Preexisting pulmonary conditions (ie, obstructive sleep apnea, asthma, chronic obstructive pulmonary disease) were present in 25% of women, and preexisting cardiac disease (ie, chronic hypertension, cardiomyopathy) were present in 17% of women.Table 1Maternal demographicsCharacteristicAll (N=64)Severe group (n=44)Critical group (n=20)*P* valueMaternal age (y)33.2±5.832.0±6.035.9±4.3.011BMI kg/m^2^33.5±7.135.3±7.329.7±5.1.003Race and ethnicity.21 Non-Hispanic black18 (28)13 (30)5 (25) Non-Hispanic white16 (25)9 (20)7 (35) Hispanic20 (31)17 (39)3 (15) Asian/Pacific Islander3 (5)1 (2)2 (10) Other7 (11)4 (9)3 (15)Singleton pregnancy63 (98)44 (100)19 (95).135Multiparous46 (72)30 (68)16 (80).33Insurance type.014 State26 (41)21 (48)5 (25) Private35 (55)23 (52)12 (60) Uninsured3 (5)0 (0)3 (15)Pulmonary pathology (OSA, asthma, COPD, etc)16 (25)12 (27)4 (20).76Cardiac disease (including chronic hypertension, cardiomyopathy)11 (17)8 (18)3 (15)1.00[^1][^2][^3]

The average gestational age at symptom onset of COVID-19 was 29.9±5.8 weeks (range 16.6--39.1 weeks), with hospital admission at 30.7±5.7 weeks. No patients included in this study were postpartum at the onset of symptoms or hospitalization. Only 23% of women with severe disease experienced symptom onset at \<24 weeks, whereas all women with critical disease experienced symptom onset at \>24 weeks (*P*=.024). Sixty-nine percent of women developed symptoms at \<34 weeks, and 86% of women developed symptoms at \<37 weeks. Most women (98%) had nasopharyngeal testing to confirm the presence of the disease. Two women with critical disease initially tested negative: 1 subsequently tested positive by bronchoalveolar lavage (after 3 negative nasopharyngeal swabs over 6 days), and the other tested positive by repeat nasopharyngeal testing ([Table 2](#tbl2){ref-type="table"} ). The vast majority of women in this study were treated with hydroxychloroquine (81%) ([Table 3](#tbl3){ref-type="table"} ). Remdesivir was used in 16 of 64 (25%) women with COVID-19 (7% with severe disease and 65% with critical disease). Convalescent serum was used in 1 patient with critical disease. Of 64 women, 15 (23%) (4% with severe disease and 55% with critical disease) received steroids for maternal indications (rather than for fetal maturity). Of 20 women with critical disease, 12 (60%) received prophylactic anticoagulants, and 8 (40%) received therapeutic anticoagulants during admission. Furthermore, of 44 women with severe disease, 25 (57%) received prophylactic anticoagulants, and 2 (5%) received therapeutic anticoagulants ([Table 3](#tbl3){ref-type="table"}).Table 2Initial findings of COVID-19CharacteristicAll (N=64)Severe group (n=44)Critical group (n=20)*P* valueGestational age at symptom onset (wk)29.9±5.829.9±6.329.7±4.6.899Symptom onset at \<24 wk10 (15.6)10 (22.7)0 (0).024Symptom onset at \<34 wk44 (68.8)29 (65.9)15 (75).47Symptom onset at \<37 wk55 (85.9)36 (81.8)19 (95).16Gestational age at hospitalization (wk)30.7±5.730.8±6.230.6±4.5.898Initial negative testing2 (3)0 (0)2 (10).094Source of sample Nasopharyngeal63 (98)44 (100)19 (95).14 BAL1 (2)0 (0)1 (5)[^4][^5][^6]Table 3Management of patients with COVID-19CharacteristicAll (N=64)Severe group (n=44)Critical group (n=20)*P* valueHydroxychloroquine52 (81)33 (75)19 (95).06Antibiotic treatment for CAP36 (56)22 (50)14 (70).14Remdesivir16 (25)3 (7)13 (65)\<.001Convalescent serum1 (2)0 (0)1 (5).31Steroids for maternal treatment15 (23)4 (9)11 (55)\<.001Anticoagulants during admission Prophylactic heparin/LMWH37 (58)25 (57)12 (60).81 Therapeutic heparin/LMWH10 (16)2 (5)8 (40)\<.001Supplemental O~2~52 (81)32 (73)20 (100).01High-flow nasal cannula16 (25)5 (11)11 (55)\<.0001BiPAP/CPAP5 (8)1 (2)4 (20).03Intubated19 (30)0 (0)19 (95)\<.001Reintubated4 (6)0 (0)4 (20).008Prone positioning4 (6)0 (0)4 (20).008ECMO0 (0)0 (0)0 (0)1.00ARDS14 (22)0 (0)14 (70)\<.001New-onset maternal cardiomyopathy0 (0)0 (0)0 (0)1.00Maternal cardiac arrest1 (2)0 (0)1 (5)\<.001Maternal mortality0 (0)0 (0)0 (0)1.00[^7][^8][^9]

In this cohort, 32 of 44 (73%) women with severe disease required O~2~ supplementation, whereas 19 of 20 (95%) women with critical disease required intubation ([Table 3](#tbl3){ref-type="table"}). In women with critical disease, 14 of 20 (70%) developed ARDS, 4 of 20 (20%) were placed in prone positioning (gestational ages 26--31 weeks), and 4 of 20 (20%) required reintubation. At the time of writing, there were no cases of cardiomyopathy or maternal mortality. One woman experienced cardiac arrest after a prolonged clinical course of the disease. She was hospitalized 14 days after symptom onset and intubated 6 days later at 20 days from symptom onset. She remained intubated for approximately 1 week, with initial signs of recovery and extubation; however, she again developed respiratory failure and experienced cardiac arrest on day 31. Cardiopulmonary resuscitation and reintubation were performed, and return of spontaneous circulation (ROSC) was achieved. She gave birth through cesarean delivery after ROSC. She was intubated for more than 2 weeks after delivery before she underwent tracheostomy placement.

In this cohort and at the time of writing, we observed that the median day (with IQR) of events from the first day of reported symptoms were as follows ([Table 4](#tbl4){ref-type="table"} ; [Figure 2](#fig2){ref-type="fig"} ): hospital admission on day 7 (IQR, 5--9), initiation of supplemental O~2~ on day 8 (IQR, 5--10), intubation (among women with critical disease) on day 9 (IQR, 6--11.5), peak respiratory support on day 8.5 (IQR, 6--11), hydroxychloroquine treatment on day 8 (IQR, 6--11), remdesivir treatment on day 10.5 (IQR, 8.8--12.5), discontinuation of supplemental O~2~ on day 13 (IQR, 9--17) (2 patients with severe disease and 11 patients with critical disease remained on supplemental O~2~ at the time of writing), and symptom resolution on day 15 (IQR, 11.5--20) (for patients who have achieved resolution). Of women who gave birth during the clinical course of the disease, delivery occurred on median disease day 10 (IQR, 1--6). When comparing women with severe disease vs women with critical disease, the clinical course was longer for the critical group, requiring the use of invasive mechanical ventilation, later cessation of supplemental oxygen (median day 12 \[IQR, 8--16\] vs day 17 \[IQR, 14--22\]; *P*=.014), last fever (median day 9 \[IQR, 6--10\] vs day 17.5 \[IQR, 14--20.5\]; *P*\<.00001), symptoms (median day 13.5 \[IQR, 10--18.5\] vs day 20 \[IQR, 15.5--22\]; *P*=.029), and later hospital discharge (median day 12 \[IQR, 9.3--15.8\] vs day 17 \[IQR, 16--25\]; *P*=.0056). The [Supplemental Table](#appsec1){ref-type="sec"} shows the disease day of events in the clinical course of COVID-19 by gestational age cutoffs.Table 4Average disease day of events in clinical course of COVID-19 (day 1, first day of onset of symptoms)CharacteristicAll (N=64)Severe group (n=44)Critical group (n=20)*P* valueInpatient admission7 (5--9)7 (5--9)7 (5--10).98Hydroxychloroquine8 (6--11)8 (6--11)8 (5.5--10.5).77Remdesivir10.5 (8.8--12.5)10 (9.5--10.5)11 (8--14).80Antibiotics for CAP8 (5--10)8 (6--10)8 (5--9).43Supplemental O~2~ started8 (5--10)8 (6--9)7 (5--10).54Peak respiratory support8.5 (6--11)8 (7--11)9 (6--11.5).89High-flow nasal cannula9 (7--11)9 (7.8--10)9 (6--11).80BiPAP/CPAP12 (10--19)10 (--)[a](#tbl4fna){ref-type="table-fn"}15.5 (10--20)---Intubation9 (6--11.5)---[b](#tbl4fnb){ref-type="table-fn"}9 (6--11.5)---Reintubation23 (20.3--25.8)---23 (20.3--25.8)---Final extubation[c](#tbl4fnc){ref-type="table-fn"}15.5 (12--18.8)---15.5 (12--18.8)---Supplemental O~2~ discontinued (n=50)[d](#tbl4fnd){ref-type="table-fn"}13 (9--17)12 (8--16)17 (14--22).014Last fever9 (7--15)9 (6--10)17.5 (14--20.5)\<.00001Hospital discharge (n=51)[e](#tbl4fne){ref-type="table-fn"}12 (10--16.5)12 (9.3--15.8)17 (16--25).0056Symptom resolution[f](#tbl4fnf){ref-type="table-fn"}15 (11.5--20)13.5 (10--18.5)20 (15.5--22).029Delivery (n=32)10 (6--13)8 (6--12)12 (6--13).35Maternal cardiac arrest (n=1)[g](#tbl4fng){ref-type="table-fn"}31---31---[^10][^11][^12][^13][^14][^15][^16][^17][^18][^19]Figure 2Median clinical courseMedian clinical course of the disease, separated by patient groups (severe and critical) and delivery (delivered and not delivered). Of note, dates of oxygen discontinuation, hospital discharge, and symptom resolution may appear falsely low because of publication before completion of disease course in some patients.*COVID-19*, coronavirus disease 2019.*Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. AJOG MFM 2020.*

If laboratory studies typically utilized to predict disease severity were used as a proxy for the most severe point in the clinical course of the disease in this study, the average peak disease day was 11 ([Table 5](#tbl5){ref-type="table"} ). Patients with critical disease had higher interleukin-6 (IL-6) levels, ferritin, fibrin split products, platelets, procalcitonin, troponins, C-reactive protein, creatine phosphokinase, and lactate dehydrogenase compared with patients with severe disease.Table 5Peak laboratory prognostic markersLaboratory values[a](#tbl5fna){ref-type="table-fn"}All (N=64)Severe group (n=44)Critical group (n=20)*P* valueIL-6 (≤1.8 pg/mL)[b](#tbl5fnb){ref-type="table-fn"}70.4±68.140.0±27.693.2±81.8.008Ferritin (5--130 ng/mL)311.0±647.5195.7±192.8469.5±967.3.0003 Disease day of peak13.0±6.111.1±4.315.2±7.4.007Fibrin split products (μg/mL)690.8±405.7843.0±181.7462.5±647.0.0006 Disease day of peak11.1±4.38.7±1.218---Liver enzymes (5--35 U/L) AST74.0±70.271.4±82.279.3±35.6.68 ALT60.2±59.853.0±58.474.8±61.5.18 Disease day of peak11.4±6.110.0±5.013.9±7.3.015Platelets (150--420 10^9^/L)350.1±153.1307.8±123.2441.2±173.7.001 Disease day of peak13.0±6.511.1±5.716.8±6.5.0007D-dimer (100--1500 ng/mL)1325.6±3388.5745.5±979.52014.4±4893.1.101 Disease day of peak13.3±6.812.3±7.614.5±6.0.26PT (10--13 s)12.9±1.412.3±0.913.8±1.6\<.0001PTT (24--38 s)[c](#tbl5fnc){ref-type="table-fn"}37.1±20.031.6±3.444.8±29.5.004 Disease day of peak11.2±6.19.0±5.013.7±6.4.002Procalcitonin (0.01--0.1 ng/mL)0.6±1.20.3±0.41.1±1.7.004 Disease day of peak9.3±5.88.4±5.310.5±6.5.18Troponin (\<0.04 mg/dL)0.7±3.00.01±0.011.5±4.5.03 Disease day of peak12.0±7.510.4±4.613.1±9.1.12CRP (\<20 mg/dL)83.7±82.043.3±45.9141.9±88.6.0001 Disease day of peak10.9±4.79.9±4.412.2±5.0.068CPK (13--101 U/L)280.4±286.592.8±83.7485.1±290.9.0001 Disease day of peak13.2±7.014.4±5.512.4±8.1.25LDH (80--450 U/L)364.9±164.3317.0±157.6467.6±131.2.0004 Disease day of peak11.1±6.09.4±5.114.6±6.4.0009[^20][^21][^22][^23][^24][^25]

[Table 6](#tbl6){ref-type="table"} shows the median duration of COVID-19 hospital characteristics for 51 discharged women. Symptoms lasted 15 days for those whose symptoms had resolved (13 days for women with severe disease vs 19 days for women with critical disease; *P*=.099). For the primary outcome, the length of hospital stay was on average 8±5 days (median duration 6 days). Women with severe disease were hospitalized for 6 days (IQR, 4.3--7), and women with critical disease were hospitalized for 12 (IQR, 7--16) days (*P*=.0031). At the time of writing, several women remained hospitalized (2 with severe disease and 11 with critical disease). Women required supplemental O~2~ for a duration of 6 days (5 \[IQR, 3--7\] days for those with severe disease and 10 \[IQR, 7--16\] for those with critical disease; *P*=.0038). Of the women who were intubated and had been discharged, the median duration of intubation was 3 days (IQR, 2--8).Table 6Duration of COVID-19 hospital characteristics for discharged womenCharacteristicAllSevere groupCritical group*P* valueSymptoms (n=29)[a](#tbl6fna){ref-type="table-fn"}15 (11--19)13 (10--19)19 (14--22).099Hospital stay6 (5--8)6 (4.3--7)12 (7--18).0031Supplemental O~2~6 (3--8)5 (3--7)10 (7--16).0038Intubation3 (2--8)N/A3 (2--8)---[^26][^27][^28][^29]

Among women who delivered during hospitalization, preterm delivery at \<34 weeks' gestation and \<37 weeks' gestation occurred in 10 (31.2%) and 19 (59.4%) women, respectively; however, when evaluating only women with critical disease who gave birth (n=17), 15 of 17 (88%) delivered preterm ([Table 7](#tbl7){ref-type="table"} ). Spontaneous preterm labor occurred in only 2 (6%) women who delivered, both in the critical group. During the clinical course of COVID-19, 50% of women delivered (34% of women with severe disease and 85% of women with critical disease) ([Table 7](#tbl7){ref-type="table"}). Maternal status was the primary indication in most cases (69% overall, 60% severe, 76% critical). The remainder was for fetal indications. Women with critical COVID-19 delivered at an earlier mean gestational age than those with severe disease (32±4 weeks' gestation vs 37±2 weeks' gestation; *P*\<.0001). There were no cases of intrauterine fetal demise. Delivery route was cesarean for 53% and 94% of women with severe and critical disease, respectively. Preeclampsia or gestational hypertension occurred in only 2 (3%) women; however, 50% of our cohort did not give birth at the time of writing. The rate of postpartum hemorrhage, defined as blood loss of \>1000 mL at time of vaginal or cesarean delivery or symptomatic hypovolemia within 24 hours associated with blood loss, was 9% overall (13% in the severe disease group and 6% in the critical disease group). The rate of presumed intrauterine infections (chorioamnionitis or endometritis) was 9% (20% in the severe disease group and 0% in the critical disease group).Table 7Pregnancy outcomesCharacteristicAll (N=64)Severe group (n=44)Critical group (n=20)*P* valueSteroids for fetal maturity16 (25)7 (16)9 (45).013Magnesium sulfate for neuroprotection6 (9)0 (0)6 (30).001Hypertensive disorders of pregnancy2 (3)2 (5)0 (0)1.00Magnesium sulfate for preeclampsia1 (2)1 (2)0 (0)1.00IUGR2 (3)0 (0)2 (10).094Stillbirth0 (0)0 (0)0 (0)1.00Oligohydramnios1 (2)1 (2)0 (0)1.00Delivered with COVID-19 during hospitalization (any cause)32 (50)15 (34)17 (85)\<.001 Delivered for maternal status22 (69)9 (60)13 (76).32 Delivered for fetal status3 (9)0 (0)3 (18).23 Delivered for obstetrical indications7 (22)6 (40)1 (6).033 Presumed chorioamnionitis or endometritis3 (9)3 (20)0 (0).092 Postpartum hemorrhage[a](#tbl7fna){ref-type="table-fn"}3 (9)2 (13)1 (6)0.590 Preterm delivery at \<37 wk19 (59)4 (27)15 (88).001 Preterm delivery at \<34 wk10 (31)0 (0)10 (59)\<.0001 Spontaneous preterm labor2 (6)0 (0)2 (12).49 PPROM1 (3)1 (7)0 (0).47 Delivery route Vaginal (includes operative vaginal delivery)8 (25)7 (47)1 (6).009 Cesarean delivery24 (75)8 (53)16 (94)[^30][^31][^32][^33]

The average neonatal birthweight was 2403.3±858.0 g (2945.8±509.2 g in the severe disease group and 1924.6±846.6 g in the critical disease group); however, the difference is likely attributed to earlier gestational age of delivery in the critical disease group. Sixty-four percent of neonates required ICU admission (40% in the severe disease group and 83% in the critical disease group). Additional neonatal outcomes are reported in [Table 8](#tbl8){ref-type="table"} . Detailed data on neonatal testing and method of testing were not available. One of 33 neonates received a diagnosis of COVID-19; in this newborn, the first test for SARS-CoV-2 at 24 hours of life was negative, but a repeat test at 48 hours returned with a positive result. The neonate showed no signs or symptoms of COVID-19.Table 8Neonatal outcomesCharacteristicAll (N=33)[a](#tbl8fna){ref-type="table-fn"}Severe group (n=15)Critical group (n=18)*P* valueGestational age at delivery (wk)34.5±4.237.7±1.631.9±3.8\<.0001Birthweight (g)[a](#tbl8fna){ref-type="table-fn"}2403.3±858.02945.8±509.21924.6±846.6\<.001NICU admission21 (63.6)6 (40)15 (83.3)0.0145-minute Apgar scores7.9±1.78.8±0.87.2±2.00.0067Neonatal death0 (0)0 (0)0 (0)1.00[^34][^35][^36][^37]

Discussion {#sec4}
==========

Principal findings {#sec4.1}
------------------

In this cohort, hospitalized pregnant women with severe or critical COVID-19 were typically admitted on disease day 7 (as measured from the first day of onset of symptoms), and the median duration of hospitalization was 6 days (6 days vs 10.5 days for women with severe and critical disease, respectively). Intubation was usually performed around disease day 9 on those who required it (approximately 2 days after hospital admission), and peak severity of nonintubated (severe) disease, determined by highest oxygen use, occurred on disease day 9. Fifty percent of women with COVID-19 delivered during the clinical course of the disease, with most deliveries due to maternal disease. About half of the women with severe disease delivered vaginally, whereas more than 90% of women with critical disease gave birth through cesarean delivery. The average gestational age at delivery was 37 weeks' gestation for women with severe disease and 32 weeks' gestation for women with critical disease. Most preterm deliveries were due to maternal status; however, data on exact etiologies were not collected. There were no maternal deaths as of this manuscript's submission.

Results in the context of what is known {#sec4.2}
---------------------------------------

The clinical course of the disease in hospitalized pregnant women with severe or critical COVID-19 seems to be similar to nonpregnant patients in the limited available studies. Of note, these comparisons are limited because the comparison criteria include a broad age range, an international community, nonpregnant patients, men, and varied indications for admission. In a series of 41 nonpregnant patients in China, hospital admission occurred on disease day 7 with onset of dyspnea on day 8. ARDS occurred on day 9, and ICU admission and mechanical ventilation on day 10.5.[@bib4] In another study of nonpregnant patients from China, the length of hospital stay was 12 days.[@bib6] In a cohort of 191 hospitalized nonpregnant patients, ARDS and ICU admission occurred on day 12, death occurred on day 18.5, and discharge occurred on day 22.[@bib5] In a cohort of 15 pregnant women in China, the interval from symptom onset to admission was 2--10 days. It must be noted that this cohort does not include any patients who required invasive mechanical ventilation.[@bib7] It is important to note that these nonpregnant populations were mostly older men, and an appropriate nonpregnant reproductive age control group is not yet available in the literature.

A current challenge lies in the prediction of patients presenting with COVID-19 who will progress to develop critical disease. Consistently across studies in nonpregnant populations, the risk of adverse outcomes increases with age and comorbidities, as well as certain laboratory values and radiologic findings.[@bib5] ^,^ [@bib13], [@bib14], [@bib15], [@bib16] In 1 study, patients requiring ICU care were more likely to have comorbid hypertension, cardiovascular disease, diabetes, and cerebrovascular disease.[@bib16] In terms of prognostic laboratory parameters, more severe lymphopenia has been noted in patients with worse outcomes.[@bib4] ^,^ [@bib5] ^,^ [@bib13] ^,^ [@bib16], [@bib17], [@bib18] Other laboratory markers linked with severe illness include elevated D-dimer, IL-6, and serum ferritin levels.[@bib5] ^,^ [@bib16] ^,^ [@bib18]

Because there are currently few reports of severe or critical COVID-19 in pregnant women, this study aimed to describe these patients and their clinical progression. In previous outbreaks of respiratory pathogens, pregnant populations experienced increased severity of illness and mortality. However, current data in the COVID-19 pandemic suggest that pregnant women experience similar, or even lower, rates of severe disease than nonpregnant patients.[@bib3] ^,^ [@bib19] Despite these early findings, there is concern that pregnant women may still be at a higher risk for complications. For example, case reports have indicated cardiomyopathy in the setting of COVID-19.[@bib20] Further data are needed on when this occurs and what predicts its occurrence. It is therefore critical to determine the unique factors in pregnant women that predict a more severe disease course to guide clinical management as well as the optimal time of delivery.

Clinical implication and research implications {#sec4.3}
----------------------------------------------

These data can help guide obstetricians in deciding when a patient should be symptomatically improving or at risk for deterioration. This is particularly important for the obstetrician who needs to consider timing and mode of delivery for patients with severe or critical COVID-19.[@bib21] Typically, attempts should be made to support the mother with oxygen as needed to maintain an oxygen saturation of \>95% and reassuring fetal monitoring. Markers of developing critical disease seem to be valid in pregnancy as well ([Table 5](#tbl5){ref-type="table"}), but further research is needed given that the physiology of pregnancy changes the normal ranges of several of these markers, with the ultimate aim of developing a tool to predict those who would benefit from delivery. One useful variable is time: in our data, pregnant women with COVID-19 who developed critical disease and needed intubation progressed quickly from admission on day 7 from symptom onset to intubation on day 9. As the standard deviation for time to intubation is 4.5 days, this means that 95% of women requiring intubation will do so within 20 days of symptom onset; this is still a long period when management is most difficult. As most women with severe disease do not develop critical illness, expectant supportive management is probably reasonable for most. On the other end of the spectrum, for women at \>34 weeks' gestation with several risk factors for critical disease such as advanced age; comorbidities including obesity, pulmonary or cardiac disease, diabetes, and others; predictive laboratory abnormalities; and predictive respiratory requirements, delivery may be indicated before onset of critical disease. These are challenging cases to manage, often requiring individualized decisions, given that we do not know whether cesarean delivery increases the severity of the clinical course and given the significant fluid shifts. A predictive tool to determine the patients with COVID-19 who would benefit from delivery during hospitalization could be developed as we acquire more data.

Strengths and limitations {#sec4.4}
-------------------------

To date, we are not aware of a larger cohort study examining specifically the disease course of hospitalized pregnant women with molecular test confirming severe or critical COVID-19. A current report of COVID-19 in pregnant women from Wuhan, China, examined 118 pregnant women with COVID-19. In this cohort, only 10 women had severe or critical disease, and no data described the clinical course of the disease.[@bib22]

Our study is limited by the nature of the cohort study (nonrandomized, lack of control group for comparison). In addition, management of patients with COVID-19 varied across institutions. Because of the urgency of obtaining information on COVID-19 in pregnancy, to guide physicians in managing patients during this pandemic, we were unable to report on long-term pregnancy or neonatal outcomes in this study.

These data are also limited by the fact that 13 women (2 with severe disease and 11 with critical disease) remained hospitalized, with several still on invasive mechanical ventilation, at the time of data collection; therefore, data on complete hospital courses and complete COVID-19 courses and pregnancy outcomes are limited. In this study, 50% of women did not give birth, which can be seen as a strength in that delivery can be delayed; however, complete outcomes on pregnancy are not yet available. In particular, effects of COVID-19 on pregnancy, including fetal growth restriction and amniotic fluid abnormalities, could not be elucidated because of the timing of data collection. Longer-term analysis will be required in the future.

Recommendations on pharmacotherapy cannot be made on the basis of these data. Larger case-control studies of the course of COVID-19 in pregnancy and randomized-controlled trials (RCTs) of interventions are necessary to best determine prognosis and management of these women. Hydroxychloroquine was used in 81% of women in our study; however, current recommendations are for its use only in the setting of clinical trials owing to unclear risks and benefits.[@bib23] Based on limited data from an RCT on the treatment of Ebola virus with remdesivir, the medication appears safe in pregnancy.[@bib24] One-fourth (25%) of our cohort received remdesivir. RCTs are ongoing on the efficacy of remdesivir for COVID-19 treatment. At some of our institutions, RCTs on the use of convalescent plasma are ongoing and include pregnant women. Use of anticoagulants remains controversial, with more research needed. By study design, no data are provided for mild COVID-19.

Conclusions {#sec4.5}
-----------

Pregnant women with severe or critical COVID-19 were typically admitted to the hospital on disease day 7 and stayed hospitalized for 6 days. Intubation was usually performed around day 9 on patients who required it, and peak severity of nonintubated disease occurred on day 9 as well. Laboratory and treatment management can reasonably follow nonpregnant guidelines; however, differing reference ranges for some laboratory values in pregnancy must be considered. This clinical course is not markedly different from that of hospitalized nonpregnant patients with COVID-19, except that days in hospital are less, with lower mortality; however, this comparison is made with nonpregnant patients who are much older on average. This suggests that pregnancy should not be considered an independent risk factor for severe or critical COVID-19. Maternal mortalities have been rarely reported so far in the literature[@bib25] ^,^ [@bib26]; however, the sample sizes of pregnancy studies remain small, and further research is necessary. Unique to pregnancy, complications such as preterm delivery and need for delivery are common for women with severe or critical COVID-19. This information is important in counseling women who received diagnosis at the early stage of disease on the potential for progression to a severe or critical stage. As management of these cases is complex, we recommend a multidisciplinary approach with maternal-fetal medicine, infectious disease, and critical care physicians. We encourage healthcare providers to use these data when deciding on pregnancy management decisions and in counseling family about the progression of COVID-19.
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[^1]: Data are presented as mean±standard deviation or n (%).

[^2]: *BMI*, body mass index; *COPD*, chronic obstructive pulmonary disease; *OSA*, obstructive sleep apnea.

[^3]: *Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies. AJOG MFM 2020*.

[^4]: Data are presented as mean±standard deviation or n (%).

[^5]: *BAL*, bronchoalveolar lavage; *COVID-19*, coronavirus disease 2019.

[^6]: *Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies. AJOG MFM 2020*.

[^7]: Data are presented as n (%).

[^8]: *ARDS*, acute respiratory distress syndrome; *BiPAP*, bilevel positive airway pressure; *CAP*, community-acquired pneumonia; *COVID-19*, coronavirus disease 2019; *CPAP*, continuous positive airway pressure; *ECMO*, extracorporeal membrane oxygenation; *LMWH*, low-molecular-weight heparin.

[^9]: *Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies. AJOG MFM 2020*.

[^10]: Data are presented as median (interquartile range).

[^11]: *BiPAP*, bilevel positive airway pressure; *CAP*, community-acquired pneumonia; *COVID-19*, coronavirus disease 2019; *CPAP*, continuous positive airway pressure.

[^12]: *Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies. AJOG MFM 2020*.

[^13]: No interquartile range for BiPAP/CPAP in severe group, as n=1

[^14]: No patients were intubated in severe group

[^15]: Five women remained intubated at the time of writing

[^16]: Two patients with severe disease remained on O~2~ and admitted at time of writing

[^17]: Eleven patients with critical disease remained on O~2~ and admitted at time of writing

[^18]: Twenty-nine patients have achieved resolution of symptoms

[^19]: Only 1 woman had maternal cardiac arrest.

[^20]: Data are presented as (reference range value in pregnancy, unit) and mean day±standard deviation.

[^21]: *ALT*, alanine aminotransferase; *AST*, aspartate aminotransferase; *CPK*, creatine phosphokinase; *CRP*, C-reactive protein; *IL-6*, interleukin-6; *LDH*, lactate dehydrogenase; *PT*, prothrombin time; *PTT*, partial thromboplastin time.

[^22]: *Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies. AJOG MFM 2020*.

[^23]: Many of the reference ranges for these laboratory tests change by trimester

[^24]: Reference range is for nonpregnant patients

[^25]: Seventy-four percent of women received prophylactic or therapeutic anticoagulation, which will alter coagulation study results.

[^26]: Data are presented as median (interquartile range) of days.

[^27]: *COVID-19*, coronavirus disease 2019; *N/A*, not applicable.

[^28]: *Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies. AJOG MFM 2020*.

[^29]: Only for women who became asymptomatic.

[^30]: Data are presented as n (%).

[^31]: *COVID-19*, coronavirus disease 2019; *IUGR*, intrauterine growth restriction; *PPROM*, preterm premature rupture of membranes.

[^32]: *Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies. AJOG MFM 2020*.

[^33]: Postpartum hemorrhage is defined as an estimated blood loss of ≥1000 mL with noticeable symptoms of blood loss/vital sign changes.

[^34]: Data are presented as mean±standard deviation or n (%).

[^35]: *NICU*, neonatal intensive care unit.

[^36]: *Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies. AJOG MFM 2020*.

[^37]: One twin pregnancy in the critical group.
